ArticleOncoTargets and therapy2016

Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis.

Stefan-Alexandru Artene et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.